Evaluating the effectiveness of intravenous ozonized saline in COVID-19 disease

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19; U07.1

• Registration Number: IRCT20200730048253N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Severe cases of Covid-19 with chest CT changes in the form of peripheral uni- or bilateral ground glass opacity(s) in combination with any of the below: RR greater than 24, O2 Sat less than 93%, BP less than 90/60, decreased level of consciousness.

Exclusion Criteria

G6PD De?ciency Coagulopathies and thrombocytopenia Hx of seizure Hypothyroidism Pancreatitis Hemophilias Acute alcohol poisoning Pregnancy and breast feeding Allergy to ozone and ozonated products

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Duration of hospitalization. Timepoint: Daily Since hospitalization. Method of measurement: patient's ?le.

Secondary Outcome Measures

Name	Time	Method
eed for ICU. Timepoint: daily since hospitalization. Method of measurement: patient's ?le.;Duration of ICU stay. Timepoint: Daily since ICU stay. Method of measurement: Patient's ?le.